CaMKII activation and regulation in adult cardiac myocytes

成人心肌细胞中 CaMKII 的激活和调节

基本信息

  • 批准号:
    10687251
  • 负责人:
  • 金额:
    $ 72.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-04-18 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary/ Abstract Ca-Calmodulin dependent protein kinase (CaMKII) is an important regulator of cardiac function, and dysfunction in pathological states, regulating ion channels, Ca transporters, myofilaments and nuclear transcription. CaMKII may normally fine-tune these processes. But in pathological conditions like heart failure (HF), chronic autonomous CaMKII activation can over-phosphorylate targets, contributing to arrhythmogenesis due to acute effects on several ion channels and Ca- handling proteins. Chronic CaMKII activation is also a hallmark of several pathological states and acute or genetic CaMKII inhibition can reduce arrhythmias and the progression of HF. Thus understanding fundamental aspects of CaMKII regulation in cardiac myocytes is critical understanding dysfunction and potential therapeutics. We and others discovered several novel post-translational modifications (PTMs) that can trap CaMKII in an activated state, rather than turning on & off rapidly with local Ca transients. Autophosphorylation, oxidation, GlcNAcylation and S-nitrosylation within a regulatory hotspot on CaMKII creates memory and autonomous activity, even when Ca/CaM falls. There are also 3 PTMs at other sites that suppress CaMKII activation. Aims 1 and 2 will directly measure how these PTMs differentially affect activation and memory of CaMKII in adult cardiac myocytes, to fill a major knowledge gap in this field. Aim 3 will test whether CaMKII S-nitrosylation at a single site is required for the heart’s intrinsic response to increase Ca transients and contraction in response to acute and chronic pressure overload (or the Anrep effect). CaMKII has well-recognized roles in HF with reduced ejection (HFrEF), but its role in HF with preserved ejection (HFpEF) is unclear. Aim 4 will directly test the engagement of CaMKII in two new HFpEF models. The proposed studies will have major impact on our understanding of how CaMKII activity is regulated in heart, in ways that promote pathology and might be targets for therapeutic intervention.
项目总结/摘要 钙调素依赖性蛋白激酶(CaMKII)是心脏功能的重要调节因子, 在病理状态下,调节离子通道、钙转运体、肌丝 和核转录。CaMKII通常可以微调这些过程。但在病理学上, 如心力衰竭(HF)等疾病,慢性自主CaMKII激活可过度磷酸化 靶点,由于对几种离子通道和Ca- 处理蛋白质慢性CaMKII激活也是几种病理状态的标志 急性或遗传性CaMKII抑制可减少心律失常和HF的进展。因此 理解心肌细胞中CaMKII调节的基本方面是至关重要的 了解功能障碍和潜在的治疗方法。我们和其他人发现了几个新的 翻译后修饰(PTM)可以将CaMKII捕获在激活状态,而不是 在局部钙瞬变的情况下快速开启和关闭。自磷酸化、氧化、GlcNAc酰化 和S-亚硝基化在CaMKII上的调节热点内产生记忆和自主 活性,即使当Ca/CaM福尔斯下降。在其他位点也有3个PTM抑制CaMKII activation.目标1和2将直接测量这些PTM如何差异性地影响激活, 在成人心肌细胞中的CaMKII的记忆,以填补在这一领域的主要知识空白。目标3 将测试CaMKII的S-亚硝基化是否需要在一个单一的网站,为心脏的内在 对急性和慢性压力反应的钙瞬变和收缩增加的反应 超负荷(或Anrep效应)。CaMKII在射血减少的HF中具有公认的作用 (HFrEF),但其在保留射血功能的HF(HFpEF)中的作用尚不清楚。目标4将直接测试 CaMKII在两个新的HFpEF模型中的参与。拟议的研究将产生重大影响 我们对CaMKII活性如何在心脏中调节的理解, 病理学,可能是治疗干预的目标。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Neuron-Restrictive Silencer Factor Limits Myocyte GαO Expression and Is Protective in Heart Failure Progression.
神经元限制性沉默因子限制肌细胞 GαO 表达并在心力衰竭进展中具有保护作用。
  • DOI:
    10.1161/circresaha.121.320597
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    20.1
  • 作者:
    Sossalla,Samuel;Bers,DonaldM
  • 通讯作者:
    Bers,DonaldM
Cardiac CaMKII activation promotes rapid translocation to its extra-dyadic targets.
  • DOI:
    10.1016/j.yjmcc.2018.10.010
  • 发表时间:
    2018-12
  • 期刊:
  • 影响因子:
    5
  • 作者:
    Wood BM;Simon M;Galice S;Alim CC;Ferrero M;Pinna NN;Bers DM;Bossuyt J
  • 通讯作者:
    Bossuyt J
CaMKII and PKA-dependent phosphorylation co-regulate nuclear localization of HDAC4 in adult cardiomyocytes.
CaMKII 和 PKA 依赖性磷酸化共同调节成体心肌细胞中 HDAC4 的核定位。
  • DOI:
    10.1007/s00395-021-00850-2
  • 发表时间:
    2021-02-15
  • 期刊:
  • 影响因子:
    9.5
  • 作者:
    Helmstadter KG;Ljubojevic-Holzer S;Wood BM;Taheri KD;Sedej S;Erickson JR;Bossuyt J;Bers DM
  • 通讯作者:
    Bers DM
Quantitative cross-species translators of cardiac myocyte electrophysiology: Model training, experimental validation, and applications.
  • DOI:
    10.1126/sciadv.abg0927
  • 发表时间:
    2021-11-19
  • 期刊:
  • 影响因子:
    13.6
  • 作者:
    Morotti S;Liu C;Hegyi B;Ni H;Fogli Iseppe A;Wang L;Pritoni M;Ripplinger CM;Bers DM;Edwards AG;Grandi E
  • 通讯作者:
    Grandi E
Mechanoelectric coupling and arrhythmogenesis in cardiomyocytes contracting under mechanical afterload in a 3D viscoelastic hydrogel.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Donald M Bers其他文献

The Difference of Calmodulin-Ryanodine Receptor Affinity Between N-terminal, Central and C-terminal RyR2-CPVT Knock-in Mice
N端、中央端和C端RyR2-CPVT敲入小鼠钙调蛋白-兰尼定受体亲和力的差异
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Hitoshi Uchinoumi;Xiaoqiong Dong;Ivanita Stefanon;Mena Said;Rogerio Faustino;Razvan L Cornea;Univ of Minnesota;Xander H.t. Wehrens; Takeshi Yamamoto;Masafumi Yano;Donald M Bers
  • 通讯作者:
    Donald M Bers
Beyond beta blockers
超越β受体阻滞剂
  • DOI:
    10.1038/nm0405-379
  • 发表时间:
    2005-04-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Donald M Bers
  • 通讯作者:
    Donald M Bers

Donald M Bers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Donald M Bers', 18)}}的其他基金

Training Program in Pharmacology
药理学培训计划
  • 批准号:
    10656570
  • 财政年份:
    2022
  • 资助金额:
    $ 72.12万
  • 项目类别:
Systems Approach to Understanding Cardiovascular Disease and Arrhythmias - Cell diversity in the cardiovascular system, cell-autonomous and cell-cell signaling
了解心血管疾病和心律失常的系统方法 - 心血管系统中的细胞多样性、细胞自主和细胞间信号传导
  • 批准号:
    10386681
  • 财政年份:
    2021
  • 资助金额:
    $ 72.12万
  • 项目类别:
Systems Approach to Understanding Cardiac Arrhythmias Mechanisms
了解心律失常机制的系统方法
  • 批准号:
    9763307
  • 财政年份:
    2019
  • 资助金额:
    $ 72.12万
  • 项目类别:
Project 2 (Bers)
项目2(Bers)
  • 批准号:
    10677715
  • 财政年份:
    2019
  • 资助金额:
    $ 72.12万
  • 项目类别:
Project 2 (Bers)
项目2(Bers)
  • 批准号:
    10006341
  • 财政年份:
    2019
  • 资助金额:
    $ 72.12万
  • 项目类别:
Modelling structural and functional heterogeneity in heart failure reveals arrhythmic impact
心力衰竭的结构和功能异质性建模揭示了心律失常的影响
  • 批准号:
    10199780
  • 财政年份:
    2019
  • 资助金额:
    $ 72.12万
  • 项目类别:
Modelling structural and functional heterogeneity in heart failure reveals arrhythmic impact
心力衰竭的结构和功能异质性建模揭示了心律失常的影响
  • 批准号:
    10449125
  • 财政年份:
    2019
  • 资助金额:
    $ 72.12万
  • 项目类别:
Project 2 (Bers)
项目2(Bers)
  • 批准号:
    10249148
  • 财政年份:
    2019
  • 资助金额:
    $ 72.12万
  • 项目类别:
Project 2 (Bers)
项目2(Bers)
  • 批准号:
    10471339
  • 财政年份:
    2019
  • 资助金额:
    $ 72.12万
  • 项目类别:
High-Throughput Screens to Discover Novel Inhibitors of Leaky RyR2 for Heart Failure Therapy
高通量筛选发现用于心力衰竭治疗的漏性 RyR2 新型抑制剂
  • 批准号:
    10064096
  • 财政年份:
    2018
  • 资助金额:
    $ 72.12万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了